TRKing down an old oncogene in a new era of targeted therapy
about
Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingNTRK gene fusions as novel targets of cancer therapy across multiple tumour typesAn Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101Implementing Genome-Driven Oncology.Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target.Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung CancerWhat hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).Tracking Down Response and Resistance to TRK Inhibitors.Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.Tyrosine receptor kinase B is a drug target in astrocytomas.Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic TherapyStructural characterization of nonactive site, TrkA-selective kinase inhibitors.Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.Implications of mitogen-activated protein kinase signaling in glioma.Small Molecules for Active Targeting in Cancer.Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.LY294002 induces in vitro apoptosis and overexpression of p75NTR in human uterine leiomyosarcoma HTB 114 cells.Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2.A review of kinase fusions in melanocytic tumors.Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.Low brain-derived neurotrophic factor levels are associated with active disease and poor prognosis in childhood acute leukemia.BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.Paired Expression Analysis of Tumor Cell Surface Antigens.Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors.Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Infantile NTRK-associated Mesenchymal Tumors.Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.Clinical and molecular insights into adenoid cystic carcinoma: Neural crest‐like stemness as a target.Clinical and molecular insights into adenoid cystic carcinoma: Neural crest-like stemness as a target.Neurotrophin Trk Receptors: New Targets for Cancer Therapy.Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.TrkAIII signals endoplasmic reticulum stress to the mitochondria in neuroblastoma cells, resulting in glycolytic metabolic adaptation.
P2860
Q26774478-B2075EA5-3820-47C1-A838-6C0DFAD2C670Q28066821-E6CF0E89-D9B5-47A5-A42B-3A1AE79F5EDEQ28265615-C530BF3A-0F5C-47AC-95F4-71E5EE8BE8A0Q30235979-2B508CF5-81DC-4606-97ED-BA61E61B0CC2Q33899971-880775C7-56FE-42ED-9D35-4DD604DAE90AQ34501607-013DE374-34A4-4893-AF21-805109DA774DQ34514469-9654780F-41A8-4AAF-AE4C-8633DF6FBE83Q35889315-C1C38BD0-3ED2-4181-A6E6-837E150EDBFDQ36066539-94BAC1B9-091B-4C01-AE51-290A487C2190Q36073551-A42EA307-1490-4D22-9CDE-45130279741BQ36553791-85CC8B81-54F5-4829-9FA8-92E2DA9C3BCCQ36629492-F0D70AD8-2B73-461C-81E8-60215CE2CE41Q37419153-5C9842E3-02E6-4F8F-93F4-2DA5B5125922Q37599025-044116A0-BBE4-406C-90FA-30F73BD32186Q37690917-F514423A-F632-44D7-BC0A-050F9B8D0808Q38371672-4F657318-46BB-40B6-8689-71AC62D0593AQ38618205-E56808FC-97AA-4C63-81C8-2C1557396E69Q38780383-BE20C06B-302B-4FAE-A2CC-B9E08BB94489Q38800617-57B6D82E-020D-4185-B08E-38D004C502B9Q38812870-9E5A828E-3A6B-4325-B5BE-A70B483CFCD5Q38819055-FCD86A9A-27C5-4B1B-895B-5DED19685965Q38943518-E204CAA4-76A6-4650-A9CE-C2332B1F4462Q38989374-01726D80-FAE2-4C7A-9264-98725CAF5101Q39002421-D26B43D0-A11B-42EE-A18C-BBF5737F9866Q39022023-5C90FAEB-5887-4792-A093-CF7922CFFB0FQ39166795-A259B8B7-287E-4716-924B-3149B3863056Q39166808-D2A7F8D6-D75C-4839-A9C8-E1CA97654578Q40173988-4A433FB4-3434-480D-8530-E44DDD15DD62Q40502136-CD3B40FF-804E-42FD-81E4-9D0FC7C52C75Q41093124-8B184BE5-7354-411B-9861-14622297AA58Q41487925-6DCBB196-A39B-4471-9873-83A4696ECE90Q41631541-7D4B68D7-F7E4-4204-8A24-A7FD37C8AAE2Q41636361-4968A983-5B06-4421-A3FF-E82917AD02AFQ46044924-2A472483-76F1-4AC1-8DC5-DD8075C1D101Q46512789-2EA0497B-D161-42D6-ABE9-AB59614C00B4Q46831652-0FA93ABF-3F26-445A-96D9-905D96895759Q47999487-CCB95347-4059-4D3E-BD78-A9CE553B3707Q50201584-9BAA9CF4-D19C-4679-9844-6FB6E631A2CFQ50251062-E01B2DD9-C7D9-41FA-9B81-0233686B5045Q50321745-1CC3A4F1-05AD-43C1-A74F-602C4BBC4D01
P2860
TRKing down an old oncogene in a new era of targeted therapy
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
TRKing down an old oncogene in a new era of targeted therapy
@ast
TRKing down an old oncogene in a new era of targeted therapy
@en
TRKing down an old oncogene in a new era of targeted therapy
@nl
type
label
TRKing down an old oncogene in a new era of targeted therapy
@ast
TRKing down an old oncogene in a new era of targeted therapy
@en
TRKing down an old oncogene in a new era of targeted therapy
@nl
prefLabel
TRKing down an old oncogene in a new era of targeted therapy
@ast
TRKing down an old oncogene in a new era of targeted therapy
@en
TRKing down an old oncogene in a new era of targeted therapy
@nl
P2093
P2860
P1433
P1476
TRKing down an old oncogene in a new era of targeted therapy
@en
P2093
Aria Vaishnavi
Robert C Doebele
P2860
P356
10.1158/2159-8290.CD-14-0765
P407
P577
2015-01-01T00:00:00Z